Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047069 | 0.83 | PPARA (0.56) | PTPN1L3MBTL1LMNAMAPK1MAPT | |
| SCHEMBL8315900 | 0.83 | L3MBTL1 (0.49) | PTPN1L3MBTL1LMNAMAPK1CASP3 | |
| SCHEMBL2448079 | 0.82 | ALOX15 (0.57) | PTPN1LMNACASP3SENP7SENP6 | |
| SCHEMBL8315903 | 0.82 | ALDH1A1 (0.51) | PTPN1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1968491 | 0.82 | KMT2A (0.55) | PTPN1L3MBTL1LMNAMAPK1MAPT | |
| SCHEMBL12697639 | 0.82 | ALDH1A1 (0.59) | PTPN1L3MBTL1LMNAMAPK1MAPT | |
| SCHEMBL12697638 | 0.81 | PLA2G4B (0.56) | PTPN1NPC1RAB9ASMN1; SMN2PLA2G4B | |
| SCHEMBL1964630 | 0.81 | PLA2G4B (0.61) | PTPN1MAPK1PLA2G4BSRD5A2 | |
| SCHEMBL8558071 | 0.80 | AOC3 (0.47) | PTPN1L3MBTL1LMNAMAPTNPC1 | |
| SCHEMBL7332590 | 0.80 | GSK3B (0.54) | PTPN1L3MBTL1LMNAMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150157605-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8853252-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8648072-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2203061-B1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8580768-B2 | Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2640381-A2 | CANNABINOID RECEPTOR ANTAGONISTS-INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | Jenrin Discovery (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130005784-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120264754-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264797-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2012-10-18 | — | — | US | disclosed |
| US-8217038-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2203061-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | Jenrin Discovery (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100152260-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100105751-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2010-04-29 | — | — | US | disclosed |
| US-7666889-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7655685-B2 | Cardiometabolic disorders like obesity, diabetes, hypertension and dyslipidemias, 3, 4-diarylpyrazole derivatives; highly selective; limited or no CNS adverse side effects, including mood disorders | JENRIN DISCOVERY, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| WO-2009059264-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090118345-A1 | Cardiometabolic disorders like obesity, diabetes, hypertension and dyslipidemias, 3, 4-diarylpyrazole derivatives; highly selective; limited or no CNS adverse side effects, including mood disorders | JENRIN DISCOVERY (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090036511-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7482470-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070259934-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005784-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | PTPN1 1598/4885STS 2556/4885L3MBTL1 4387/4885 |
| US-20090118345-A1 | Cardiometabolic disorders like obesity, diabetes, hypertension and dyslipidemias, 3, 4-diarylpyrazole derivatives; highly selective; limited or no CNS adverse side effects, including mood disorders | CNR2, CNR1, GPR119 | PTPN1 876/4885STS 3820/4885L3MBTL1 3142/4885 |
| US-20120264754-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | PTPN1 1385/4885STS 3603/4885L3MBTL1 4419/4885 |
| US-20070259934-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | PTPN1 1598/4885STS 2556/4885L3MBTL1 4387/4885 |
| US-20100105751-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | PTPN1 1711/4885STS 2683/4885L3MBTL1 4275/4885 |
| US-20120264797-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | PTPN1 1711/4885STS 2683/4885L3MBTL1 4275/4885 |
| US-20090036511-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | PTPN1 1598/4885STS 2556/4885L3MBTL1 4387/4885 |
| US-20100152260-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | PTPN1 1598/4885STS 2556/4885L3MBTL1 4387/4885 |
| US-20150157605-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | PTPN1 1711/4885STS 2683/4885L3MBTL1 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.